Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK1 | P06870 | 2/20 | 0.76 |
| ▸ | TP53 | P04637 | 1/20 | 0.73 |
| ▸ | PLAU | P00749 | 8/20 | 0.68 |
| ▸ | KLK8 | O60259 | 2/20 | 0.68 |
| ▸ | F10 | P00742 | 2/20 | 0.68 |
| ▸ | PLG | P00747 | 2/20 | 0.68 |
| ▸ | KLK4 | Q9Y5K2 | 2/20 | 0.68 |
| ▸ | F2 | P00734 | 1/20 | 0.68 |
| ▸ | PLAT | P00750 | 1/20 | 0.68 |
| ▸ | KLK2 | P20151 | 1/20 | 0.67 |
| ▸ | ELANE | P08246 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15397885 | 0.87 | KLK1 (0.56) | KLK1TP53PLAUKLK8F10 | |
| SCHEMBL17126245 | 0.84 | KLK1 (0.83) | KLK1TP53PLAUKLK8F10 | |
| SCHEMBL17113956 | 0.84 | KLK1 (0.51) | KLK1TP53PLAUKLK8F10 | |
| SCHEMBL11760035 | 0.82 | PLAU (0.49) | KLK1TP53PLAUKLK8F10 | |
| SCHEMBL1364914 | 0.82 | KLK1 (0.78) | KLK1TP53PLAUKLK8F10 | |
| SCHEMBL18718105 | 0.82 | KLK1 (0.50) | KLK1TP53PLAUKLK8F10 | |
| SCHEMBL4297455 | 0.81 | PLAU (1.00) | KLK1TP53PLAUKLK8F10 | |
| SCHEMBL4295336 | 0.81 | PLAU (1.00) | KLK1TP53PLAUKLK8F10 | |
| Hydrochloric Acid SCHEMBL7390446 | 0.80 | PLAU (0.98) | KLK1TP53PLAUKLK8F10 | |
| SCHEMBL17126717 | 0.79 | PLAU (0.78) | KLK1TP53PLAUKLK8F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017527-B2 | KLK4 inhibitors | UNIVERSITEIT ANTWERPEN (BE) | 2018-07-10 | — | — | US | disclosed |
| US-20170101427-A1 | NOVEL KLK4 INHIBITORS | UNIVERSITEIT ANTWERPEN (BE) | 2017-04-13 | — | — | US | disclosed |
| US-20170101427-A1 | NOVEL KLK4 INHIBITORS | UNIVERSITEIT ANTWERPEN (BE) | 2017-04-13 | — | — | US | disclosed |
| WO-2015144933-A1 | NOVEL KLK4 INHIBITORS | UNIVERSITEIT ANTWERPEN (BE) | 2015-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10017527-B2 | KLK4 inhibitors | KLK4, KLK3, KLK1 | KLK1 3/4885TP53 1931/4885PLAU 1275/4885 |
| US-20170101427-A1 | NOVEL KLK4 INHIBITORS | KLK4, KLK3, KLK1 | KLK1 3/4885TP53 1893/4885PLAU 1428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.